Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NOVT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNovanta closes $1.2B Riverpoint Medical acquisition, doubles recurring medical revenue
Filed July 27, 2026 · Period ending July 22, 2026 · ~1 min read
Key Changes
-
high
Closed acquisition of Riverpoint Medical for ~$1.2B cash plus $250M milestone due Jan 2027; funded with $616M debt and cash on hand, bringing total debt to $854.7M.
Item 2.01, Item 2.03 verify on EDGAR → -
high
Acquisition expected to double recurring medical consumables revenue to ~$300M and push medical end-market exposure to 60% of total revenue; Riverpoint growing revenue and cash flow at twice Novanta's rate.
Exhibit 99.1 view on EDGAR → -
high
Deal expected to contribute $0.18-$0.25 adjusted EPS in 2027, generate high single-digit ROIC by year three, and be immediately accretive to organic growth, adjusted gross margins, and cash flows.
Exhibit 99.1 view on EDGAR → -
medium
Management believes acquisition unlocks $2B incremental addressable market through shared OEM customer relationships and strengthens FDA-registered manufacturing footprint.
Exhibit 99.1 view on EDGAR → -
medium
Debt borrowed under existing credit facilities matures June 2030 with no prepayment penalty, providing flexibility to manage the increased leverage.
Item 2.03 verify on EDGAR →
Summary
Novanta completed its acquisition of Riverpoint Medical, a leader in minimally invasive surgical consumables, for approximately $1.2 billion in cash plus a $250 million milestone payment due January 2027. The company funded the deal with $616 million in new borrowings under existing credit facilities and cash on hand, bringing total consolidated debt to $854.7 million.
The debt matures in June 2030 with no prepayment penalty. The acquisition represents a significant strategic shift for Novanta, expected to double recurring medical consumables revenue to roughly $300 million and increase medical end-market exposure to 60% of total revenue.
Management states Riverpoint is growing revenue and cash flow at twice Novanta's rate and believes the deal unlocks a $2 billion incremental addressable market through shared OEM customer relationships. The transaction is projected to contribute $0.18-$0.25 in adjusted EPS in 2027 and generate a high single-digit return on invested capital by year three. Retail holders should monitor whether the acquired business delivers the projected growth acceleration and margin accretion to justify the increased leverage. The $854.7 million debt load and pending $250 million milestone payment represent meaningful financial commitments that will require strong cash flow generation from both the base business and the acquisition to service comfortably.
Section-by-Section Diff
Event · Item 2.01 — Completion of Acquisition or Disposition of Assets
Item 2.01 — Completion of Acquisition or Disposition of Assets filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On July 23, 2026, the closing of the Transaction (the “Closing”) occurred.
Novanta closed its previously announced acquisition of Runway Buyer, LLC on July 23, 2026. The transaction was first disclosed in a June 8, 2026 8-K and has now been completed.
Added in current filing · verify on EDGAR →
Subject to the terms and conditions of the Purchase Agreement, at the Closing, the Buyer Parties paid the Seller approximately $1.2 billion in cash (the “Closing Consideration”), subject to customary adjustments based on cash, working capital, debt and transaction expenses of Runway Buyer as of the Closing. In addition, a milestone payment amount of $250.0 million remains payable by the Buyer Parties to Seller on or before January 8, 2027.
Novanta paid approximately $1.2 billion in cash at closing, subject to customary working capital and other adjustments. An additional $250 million milestone payment is due by January 8, 2027. The total consideration structure is approximately $1.45 billion.
Event · Item 1.01 — Entry into a Material Definitive Agreement
8-K incorporates prior Item 1.01 disclosure into Item 2.01; no new material event disclosed in this filing.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Item 1.01 of the Previous Form 8-K is incorporated into this Item 2.01 by reference.
This 8-K filing incorporates by reference Item 1.01 from a previous Form 8-K into Item 2.01 (Completion of Acquisition or Disposition of Assets). No new substantive disclosure is provided in this filing; the material event details are contained in the referenced prior filing.
Event · Item 2.03 — Creation of a Direct Financial Obligation
Item 2.03 — Creation of a Direct Financial Obligation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On July 22, 2026, to fund the Transaction, Intermediate Parent borrowed $616.0 million in the aggregate under its revolving credit facility and delayed draw term loan facility under its Fourth Amended and Restated Credit Agreement (the “Credit Agreement”) and funded the remaining consideration with cash on hand.
The company borrowed $616.0 million under existing credit facilities to fund an unspecified transaction, supplementing the borrowing with cash on hand. The borrowings are split between a revolving credit facility and a delayed draw term loan facility under the company's Fourth Amended and Restated Credit Agreement.
Added in current filing · verify on EDGAR →
Borrowings under the revolving credit facility and delayed draw term loan facility are due upon maturity of the Credit Agreement in June 2030 and may be repaid at any time prior to maturity without prepayment penalty.
The new borrowings mature in June 2030 and can be repaid early without penalty, providing the company with financial flexibility to manage its debt load over the next four years.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today announced that it has completed the acquisition of Riverpoint Medical (“Riverpoint Medical” or “Riverpoint”) from Arlington Capital Partners.
Novanta closed its acquisition of Riverpoint Medical, a category leader in minimally invasive surgical consumables including advanced surgical fibers for sports medicine, trauma, and cardiovascular applications. The deal was purchased from private equity firm Arlington Capital Partners.
Show 1 minor / wording change
Added in current filing · view on EDGAR →
Riverpoint Medical will be reported under Novanta’s Medical Solutions operating segment.
Riverpoint Medical will be integrated into and reported under Novanta's Medical Solutions operating segment for financial reporting purposes.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 28, 2026 · How we verify